Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Freeline

- PMLiVE

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

Former Horizon chief Darrin Disley to lead the company through series A round

Cell and gene therapy

Tackling the manufacturing cost and complexity challenges

- PMLiVE

How to pay for very high cost, curative drugs? ICER and NICE put their heads together

Three HTA bodies seek answers to future value models

- PMLiVE

Editas CEO exits the CRISPR firm ahead of first clinical trial

Shares in company and competitors sink

- PMLiVE

FDA expecting boom in cell and gene therapies

Pledges clampdown on developers working outside regulations

- PMLiVE

Novartis buys CellforCure to bolster cell, gene therapy

Move would make existing partner an in-house capability

- PMLiVE

Ex-Pharmacyclics CEO invests $25m in Summit

After Duchenne drug failure, UK biotech looks to new anti-infective

- PMLiVE

Astellas makes another gene therapy play with Juventas deal

Targeting faecal incontinence, which affects 50m worldwide

- PMLiVE

Digital tech from Autolus and Oxford BioMedica to speed advanced therapies

UK funds efforts to make country a leader in cell and gene therapy

- PMLiVE

UniQure skyrockets on haemophilia B gene therapy data

Competition with Pfizer and Spark rival heats up

- PMLiVE

MedCity sets up advanced therapy research network

Aims to capitalise on UK's expertise in cutting-edge field

- PMLiVE

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

Trial could begin by year end

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links